9.04
price down icon5.44%   -0.52
after-market After Hours: 9.04
loading
Entrada Therapeutics Inc stock is traded at $9.04, with a volume of 143.37K. It is down -5.44% in the last 24 hours and down -24.29% over the past month.
See More
Previous Close:
$9.56
Open:
$9.43
24h Volume:
143.37K
Relative Volume:
1.32
Market Cap:
$406.02M
Revenue:
$239.40M
Net Income/Loss:
$104.44M
P/E Ratio:
3.0541
EPS:
2.96
Net Cash Flow:
$-18.50M
1W Performance:
-16.30%
1M Performance:
-24.29%
6M Performance:
-43.43%
1Y Performance:
-36.20%
1-Day Range:
Value
$8.85
$9.43
1-Week Range:
Value
$8.85
$10.87
52-Week Range:
Value
$8.85
$21.79

Entrada Therapeutics Inc Stock (TRDA) Company Profile

Name
Name
Entrada Therapeutics Inc
Name
Phone
857-305-1825
Name
Address
ONE DESIGN CENTER PLACE, BOSTON
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-08-12
Name
Latest SEC Filings
Name
TRDA's Discussions on Twitter

Compare TRDA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TRDA
Entrada Therapeutics Inc
9.04 406.02M 239.40M 104.44M -18.50M 2.96
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-06-24 Initiated ROTH MKM Buy
Jan-05-24 Initiated Oppenheimer Outperform
Apr-03-23 Initiated H.C. Wainwright Buy

Entrada Therapeutics Inc Stock (TRDA) Latest News

pulisher
09:50 AM

Entrada Therapeutics Gains Momentum Amid Exon-Skipping Advances and Regulatory Approvals - TipRanks

09:50 AM
pulisher
07:36 AM

Entrada Therapeutics stock rating holds with $20 target By Investing.com - Investing.com UK

07:36 AM
pulisher
Mar 28, 2025

Entrada Therapeutics stock hits 52-week low at $9.74 By Investing.com - Investing.com UK

Mar 28, 2025
pulisher
Mar 28, 2025

Charles Schwab Investment Management Inc. Boosts Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

Mar 28, 2025
pulisher
Mar 24, 2025

Roth/MKM maintains Buy on Entrada stock, $23 target By Investing.com - Investing.com Canada

Mar 24, 2025
pulisher
Mar 24, 2025

Positive Outlook on Entrada Therapeutics Inc Due to Promising Developments in Duchenne Muscular Dystrophy Treatment - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Entrada Therapeutics gets approval to start trial of its DMD treatment in the UK (TRDA:NASDAQ) - Seeking Alpha

Mar 24, 2025
pulisher
Mar 24, 2025

Entrada Therapeutics rises on UK approval for muscle-wasting drug study - TradingView

Mar 24, 2025
pulisher
Mar 24, 2025

Entrada’s ENTR-601-45 gains clearance in UK to enter clinic for Duchenne muscular dystrophy - BioWorld MedTech

Mar 24, 2025
pulisher
Mar 24, 2025

Entrada Therapeutics begins Duchenne study in UK By Investing.com - Investing.com Australia

Mar 24, 2025
pulisher
Mar 24, 2025

Entrada Therapeutics begins Duchenne study in UK - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Entrada Therapeutics Gains UK Approval for DMD Study - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping - The Manila Times

Mar 24, 2025
pulisher
Mar 24, 2025

Major Breakthrough: Entrada's DMD Drug Gets Green Light for UK Clinical Trials - Stock Titan

Mar 24, 2025
pulisher
Mar 23, 2025

Bank of New York Mellon Corp Lowers Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Entrada Therapeutics stock hits 52-week low at $10.21 - Investing.com

Mar 21, 2025
pulisher
Mar 19, 2025

Entrada Therapeutics CFO sells $19,035 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Entrada Therapeutics CFO sells $19,035 in stock - Investing.com India

Mar 19, 2025
pulisher
Mar 13, 2025

Long Term Trading Analysis for (TRDA) - news.stocktradersdaily.com

Mar 13, 2025
pulisher
Mar 11, 2025

Entrada Therapeutics stock hits 52-week low at $10.25 By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Entrada Therapeutics stock hits 52-week low at $10.25 - Investing.com

Mar 11, 2025
pulisher
Mar 05, 2025

Entrada Therapeutics (TRDA) Expected to Announce Earnings on Wednesday - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Entrada Therapeutics stock hits 52-week low at $11.3 amid market shifts - Investing.com Canada

Mar 04, 2025
pulisher
Mar 04, 2025

Brokers Offer Predictions for TRDA Q4 Earnings - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

What is William Blair’s Estimate for TRDA Q1 Earnings? - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

Results: Entrada Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st

Mar 02, 2025
pulisher
Mar 02, 2025

Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next - Yahoo Finance

Mar 02, 2025
pulisher
Feb 28, 2025

Entrada Therapeutics (NASDAQ:TRDA) Releases Earnings Results, Beats Estimates By $0.69 EPS - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Entrada Therapeutics' (TRDA) Buy Rating Reiterated at HC Wainwright - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Entrada Therapeutics: Regulatory Progress and Strategic Trials Drive Buy Rating - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Entrada Therapeutics reports Q4 EPS 3c vs. (29c) last year - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Oppenheimer maintains Entrada stock Outperform with $30 target - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Oppenheimer maintains Entrada stock Outperform with $30 target By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Entrada Therapeutics Reports Strong 2024 Financial Results - TipRanks

Feb 28, 2025
pulisher
Feb 27, 2025

Entrada Therapeutics earnings beat by $0.70, revenue fell short of estimates - Investing.com UK

Feb 27, 2025
pulisher
Feb 27, 2025

Entrada Therapeutics sees cash runway into 2Q27 - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Entrada Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Feb 27, 2025
pulisher
Feb 27, 2025

HC Wainwright Reiterates Buy Rating for Entrada Therapeutics (NASDAQ:TRDA) - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Allspring Global Investments Holdings LLC Lowers Stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

Feb 26, 2025
pulisher
Feb 26, 2025

Entrada Therapeutics Receives Buy Rating Amid Regulatory Progress and Promising Clinical Developments - TipRanks

Feb 26, 2025
pulisher
Feb 24, 2025

FDA authorizes Entrada’s DMD drug study By Investing.com - Investing.com Australia

Feb 24, 2025
pulisher
Feb 24, 2025

Optimistic Outlook on Entrada Therapeutics: FDA Lifts Hold on ENTR-601-44, Paving Way for Key Trials - TipRanks

Feb 24, 2025
pulisher
Feb 24, 2025

FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy - Benzinga

Feb 24, 2025
pulisher
Feb 24, 2025

Entrada Therapeutics Says FDA Lifted Clinical Hold on ENTR-601-44; Shares Advance Premarket - Marketscreener.com

Feb 24, 2025
pulisher
Feb 24, 2025

Entrada rises as FDA removes clinical hold on muscle-wasting therapy - TradingView

Feb 24, 2025
pulisher
Feb 24, 2025

FDA authorizes Entrada's DMD drug study - Investing.com India

Feb 24, 2025
pulisher
Feb 24, 2025

FDA authorizes Entrada’s DMD drug study - Investing.com

Feb 24, 2025
pulisher
Feb 24, 2025

Entrada Therapeutics Receives FDA Approval for DMD Study - TipRanks

Feb 24, 2025
pulisher
Feb 24, 2025

FDA authorizes Entrada's DMD drug study By Investing.com - Investing.com South Africa

Feb 24, 2025
pulisher
Feb 24, 2025

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 - The Manila Times

Feb 24, 2025

Entrada Therapeutics Inc Stock (TRDA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):